Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;13(13):1873-83.
doi: 10.1517/14656566.2012.705831. Epub 2012 Jul 9.

Treatment Strategies for Myasthenia Gravis: An Update


Treatment Strategies for Myasthenia Gravis: An Update

Jordi Díaz-Manera et al. Expert Opin Pharmacother. .


Introduction: New treatments for immune mediated diseases have increased notably in the last 10 years. Monoclonal antibodies directed against different components of the immune system have appeared, along with new drugs from the haematology field. In the case of myasthenia gravis (MG), many of these new treatments have been used in experimental animal models and also in patients.

Areas covered: This manuscript reviews the progress in the field of MG treatment achieved in the last 5 years. Firstly, our current treatment protocol is introduced. Secondly, new data from recent randomized trials and case series of patients treated with methotrexate, cyclophosphamide, rituximab or improved systems of apheresis is reported. Finally, all future treatments are discussed that are currently under evaluation in preclinical animal models of experimental autoimmune MG.

Expert opinion: Evidence supporting the use of methotrexate and rituximab in MG has been published recently, in addition to conflicting randomized trials that were not successful, evaluating the use of tacrolimus as a steroid sparing agent. New promising treatments are currently under evaluation in clinical trials, such as belimumab and eculizumab.

Similar articles

See all similar articles

Cited by 4 articles

MeSH terms


LinkOut - more resources